A “Black-Box Warning” about the increased risk of lower limb amputations was added to the drug labels for Invokana and Invokamet in July 2017. Since that time there has been a mix of opinions expressed in the medical literature about whether or not lower limb amputations are a side effect of all diabetes medicines in the sodium-glucose … [Read more...]
Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitors class diabetes medicines such as Jardiance and Farxiga in addition to Invokana. For example, from this recent Medscape news report, “Canagliflozin (Invokana) Gets FDA Nod for CV … [Read more...]
Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2) inhibitor class, such as canagliflozin (Invokana / Invokamet), empagliflozin (Jardiance / Glyxambi / Synjardy), and dapagliflozin (Farxiga / Xigduo / … [Read more...]
“Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
In September 2017 Health Canada required Janssen, the drug company responsible for Invokana and Invokamet, to send a Dear Healthcare Professional Letter — commonly referred to as a “Dear Doctor” letter — about the lower limb amputations side effect. Here are some of the points presented in this September 2017 Janssen letter to Canadian … [Read more...]
FDA Reports Show Extent And Nature of Invokana-Amputation Side Effect
A British medical journal, The Lancet Diabetes & Endocrinology, published this Correspondence item on July 18, 2017, “SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System”. The main point of that article is set forth in this excerpt: In summary, this pharmacovigilance analysis confirms that use of canagliflozin, but … [Read more...]
Can SGLT-2 Inhibitor Diabetes Drugs Increase Your Risk of Stroke?
While we have frequently discussed DKA, kidney damage, and amputations as possible side effects of diabetes drugs in the SGLT-2 inhibitors class -- such as Farxiga, Invokana, Jardiance -- strokes and thromboembolic events are also considered potential harmful effects of these drugs. Based on FAERS reports received during the second quarter of … [Read more...]